Enliven Therapeutics, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal: Lori Kunkel, M.D.

Enliven Therapeutics, Inc.’s own tally for this item (“Elect Director: Lori Kunkel, M.D.”): 32,788,330 for, 17,898,297 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Two Class III Directors Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders or until their successor is duly elected and qualified or until their earlier death, resignation or removal.”
Support: 65% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 8,893,647 for, 3,600,689 withheld, 33 abstained.

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

Description as filed by funds: To elect the two Class III directors named in the accompanying proxy statement to serve until the 2029 annual meeting of stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal: Richard Fair, M.B.A.

Enliven Therapeutics, Inc.’s own tally for this item (“Elect Director: Richard Fair, M.B.A.”): 50,534,439 for, 152,188 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Two Class III Directors Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders or until their successor is duly elected and qualified or until their earlier death, resignation or removal.”
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 12,476,873 for, 17,497 withheld.

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

Description as filed by funds: To amend our amended and restated certificate of incorporation, as amended, to increase our authorized shares of common stock from 100,000,000 shares to 200,000,000 shares.

Enliven Therapeutics, Inc.’s own tally for this item (“3. Amendment to the Amended and Restated Certificate of Incorporation, as Amended, to Increase the Company's Authorized Shares of Common Stock from 100,000,000 Shares to 200,000,000 Shares”): 54,711,846 for, 373,215 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved the amendment to the Amended and Restated Certificate of Incorporation, as amended, to increase the Company's authorized shares of common stock from 100,000,000 shares to 200,000,000 shares.”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 12,460,917 for, 33,449 against, 3 abstained.

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.

Description as filed by funds: To approve, in an advisory (non- binding) vote, the compensation of our named executive officers as disclosed in our proxy statement.

Enliven Therapeutics, Inc.’s own tally for this item (“4. Approval, in an Advisory (Non-binding) Vote, the Compensation of the Company's Named Executive Officers as Disclosed in the Proxy Statement”): 47,572,153 for, 3,093,447 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved, in an advisory (non-binding) vote, the compensation of the Company's named executive officers as disclosed in the Company's proxy statement.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 56 managers: 12,022,938 for, 453,944 against, 17,488 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 149 managers: 43,622,487 for, 2,374,113 against, 705 abstained, 11,964 1 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To approve, in an advisory (non- binding) vote, the frequency of future stockholder advisory votes on the compensation of our named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 56 managers: 32,653 for, 17,488 abstained, 12,200,897 1 year, 243,238 3 year, 94 unknown. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 146 managers: 683,501 for, 194 against, 45,049,036 1 year, 70,973 3 year. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.

Enliven Therapeutics, Inc.’s own tally for this item (“2. Ratification of the Appointment of Independent Registered Public Accounting Firm”): 56,119,493 for, 795 against — passed, per its Form 8-K filed June 10, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 56 asset managers below reported 12,476,882 for, 17,488 abstained.

Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.